Mgd009 (Not yet branded)
Other Medications
Description
MGD009 is a bispecific antibody that simultaneously targets B7-H3 and CD3 proteins for the treatment of solid tumors including colorectal cancer. This dual-targeting immunotherapy is designed to redirect T-cells to attack cancer cells that express the B7-H3 protein on their surface. MGD009 belongs to a class of engineered antibodies that create an immunological bridge between immune effector cells and tumor cells.
Mechanism of Action
MGD009 binds to B7-H3, a protein overexpressed on many solid tumor cells including colorectal cancers, while simultaneously engaging CD3 receptors on T-cells. This dual binding creates a cytolytic synapse that activates T-cells and directs them to kill B7-H3-expressing cancer cells through cytotoxic mechanisms.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 Estado EMA | Experimental |
 Acceso España | med_spain_not_available |
| Administration | IV |
| Clinical Trials | 1 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.